Axsome Therapeutics (NASDAQ: AXSM) Reports Strong Q3 2026 Earnings with Revenue and EPS Beat
Axsome Therapeutics reported a Q3 2026 loss of $0.25 per share, significantly better than the estimated $0.63 per share loss. The biopharmaceutical company's revenue reached $259.7 million, surpassing analyst estimates and growing 52% year-over-year. Key products AUVELITY, SUNOSI, and SYMBRAVO…